Who is sponsoring NCT03263130?

NCT03263130 is sponsored by Gelb, Arthur F., M.D..

What drugs are being tested in NCT03263130?

Interventions in NCT03263130: As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap.

What condition does NCT03263130 study?

NCT03263130 studies COPD, Emphysema, Asthma COPD Overlap, Emphysema.

Is NCT03263130 still recruiting?

NCT03263130 is currently recruiting now. Last updated 27 October 2023.

Last reviewed 2023-10-27 · How we verify

NCT03263130

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

Recruiting now Last updated 27 October 2023

What this trial tests

trial testing As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap in COPD, Emphysema, Asthma COPD Overlap in 60 participants. Currently enrolling.

Timeline

1 January 2017

Primary endpoint
1 January 2027

1 December 2027

Quick facts

Lead sponsor	Gelb, Arthur F., M.D.
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	60
Start date	1 January 2017
Primary completion	1 January 2027
Estimated completion	1 December 2027
Sites	2 locations across United States

Drugs / interventions tested

As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap

Conditions studied

COPD, Emphysema, Asthma COPD Overlap — all drugs for COPD, Emphysema, Asthma COPD Overlap →
Emphysema — all drugs for Emphysema →

Sponsor

Gelb, Arthur F., M.D. — full company profile →

Who can join

30 and older, any sex, with COPD, Emphysema, Asthma COPD Overlap or Emphysema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Gelb, Arthur F., M.D. trials

Trials by the same sponsor.

NCT03839992 — Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03263130 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gelb, Arthur F., M.D.
Last refreshed: 27 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03263130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing